Evaluating the Effects of Pioneer Accountable Care Organizations on Medicare Part D Drug Spending and Utilization
Datos Bibliográficos
| ID | 9103087 |
|---|---|
| Autores | Yuting Zhang (0000-0002-6460-6779, University of Pittsburgh, autor de correspondencia), Kadin J Caines (Centers for Medicare and Medicaid Services, Office of Enterprise Data and Analytics, Baltimore, MD), Kadin Caines (Centers for Medicare and Medicaid Services), Christopher A Powers (Centers for Medicare and Medicaid Services, Office of Enterprise Data and Analytics, Baltimore, MD) |
| Año | 2017 |
| Volumen | 55 |
| Número | 5 |
| Páginas | 470-475 |
| Fecha de publicación | 2017-05-01 |
| Peer Reviewed | Sí |
| Open Access | No |
| Tipo | ARTICLE |
| Revista | Medical Care (JOURNAL) |
| Identificadores de la revista | ISSN: 0025-7079 • E-ISSN: 1537-1948 |
| Editorial | Ovid Technologies (Wolters Kluwer Health) (PUBLISHER) |
| DOI | 10.1097/mlr.0000000000000686 |
| PMID | 28060052 |
| OpenAlex | W2569297303 |
| Idioma | EN |
| Citas recibidas | 3 |
| Referencias citadas | 22 |
BACKGROUND: The improvement of medication use is a critical mechanism that accountable care organization (ACO) could use to save overall costs. Currently pharmaceutical spending is not part of the calculation for ACO-shared savings and risks. Thus, ACO providers may have strong incentives to prescribe more medications hoping to avoid expensive downstream medical costs. METHODS: We designed a quasinatural experiment study to evaluate the effects of Pioneer ACOs on Medicare Part D spending and utilization. Medicare fee-for-service beneficiaries with Part D drug coverage who were aligned to a Pioneer ACO were compared with a random 5% sample of non-ACO beneficiaries. Outcomes included changes in Part D spending, number of prescription fills, percent of brand medications, and total Part A and B medical spending. We utilized a generalized linear model with a difference-in-differences approach to estimate 2011-2012 changes in these outcomes among beneficiaries aligned with Pioneer ACOs, adjusting for all beneficiary-level demographics, income and insurance status, clinical characteristics, and regional fixed effects. RESULTS: Being in an ACO did not significantly affect Part D spending (-$23.52; P=0.19), total prescriptions filled (-0.12; P=0.27), and the percent of claims for brand-name drugs (0.06%; P=0.23). The ACO group was associated with savings in Parts A and B spending of $345 (P<0.0001) per person per year. CONCLUSIONS: We found that beneficiaries aligned to Pioneer ACOs were not associated with changes in pharmaceutical spending and use, but were associated with savings in Parts A and B spending in 2012
Business · Drug · Family medicine · MEDLINE · Political science · Healthcare Policy and Management · Medication Adherence and Compliance · Medicine · Pharmaceutical Economics and Policy · Pharmacology
| Obras citantes distintas | 3 |
|---|---|
| Citas por año | 0,43 |
| Intervalo de citas | 2019 - 2022 (4) |
| Velocidad de citación | historical |
| Altamente citado | No |
| Tipos de cita | Neutras: 2 |